Abstract
Dysrhythmias are common during acute myocardial infarction (AMI); these range from benign premature beats to ventricular fibrillation (VF). Reports from the early coronary-care unit (CCU) era suggested that the majority of patients with AMI have some abnormality of heart rhythm (1). In recent years, the management of arrhythmias associated with AMI has evolved significantly, along with other elements of CCU care. Malignant ventricular arrhythmias remain the cause of most prehospital sudden deaths as a result of AMI.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Spann JF, Moellering RC, Haber E, Wheeler EO. Arrhythmias in acute myocardial infarction: a study utilizing an electrocardiographic monitor for automatic detection and recording arrhythmias. N Engl J Med 1964; 271: 427–431.
Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on management of acute myocardial infarction). Available at http://www.acc.org/clinical/guidelines andhttp://americanheart.org.
Weiss JN, Nademanee K, Stevenson WG, Singh B. Ventricular arrhythmias in ischemic heart disease. Ann Int Med 1991; 114: 784–797.
Clayton RH, Murray A, Higham PD, Campbell RWF. Self-terminating ventricular arrhythmias—a diagnostic dilemma. Lancet 1993; 341: 93–95.
Lawrie DM, Higgins MR, Godman MJ, et al. Ventricular fibrillation complicating acute myocardial infarction. Lancet 1968; 2: 523–528.
Volpi A, Cavalli A, Santoro L, et al. Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction—results of the gruppo italiano per lo studio della sopravvivenza nell’infarcto miocardico (GISSI-2) database. Am J Cardiol 1998; 82: 265–271.
Tofler GH, Stone PH, Muller JE, et al. Prognosis after cardiac arrest due to ventricular tachycardia or ventricular fibrillation associated with acute myocardial infarction (The MILIS Study). Am J Cardiol 1987; 60: 755–761.
Goldberg RJ, Gore JM, Haffajee CI, Alpert JS, Dalen JE. Outcome after cardiac arrest during acute myocardial infarction. Am J Cardiol 1987; 59: 251–255.
Nicod P, Gilpin E, Dittrich, et al. Late clinical outcome in patients with early ventricular fibrillation after myocardial infarction. J Am Coll Cardiol 1988; 11: 464–470.
Behar S, Reicher-Riess H, Shecter M, et al. Frequency and prognostic significance of secondary ventricular fibrillation complicating acute myocardial infarction. Am J Cardiol 1993; 71: 152–156.
Brezens M, Elyassov S, Elimelech I, Raguin N. Comparison of patients with acute myocardial infarction with and without ventricular fibrillation. Am J Cardiol 1996; 78: 948–950.
Zehender M, Kasper W, Kauder E, et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 1993; 328: 981–988.
Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994; 330: 1211–1217.
Volpi A, Maggioni A, Franziosi MG, Pampallona S, Mauri F, Tognoni G. In-hospital prognosis of patients with acute myocardial infarction complicated by primary ventricular fibrillation. N Engl J Med 1987; 317: 257–261.
Volpi A, Cavalli A, Santoro E, Tognoni G, and GISSI Investigators. Incidence and prognosis of secondary ventricular fibrillation in acute myocardial infarction. Circulation 1990; 82: 1279–1288.
Antman EM, Berlin JA. Declining incidence of ventricular fibrillation in myocardial infarction: implications for the prophylactic use of lidocaine. Circulation 1992; 86: 764–773.
Chiriboga D, Yarzebski J, Goldberg RJ, Gore JM, Alpert JS. Temporal trends (1975 through 1990) in the incidence and case-fatality rate of primary ventricular fibrillation complicating acute myocardial infarction—A communitywide perspective. Circulation 1994; 89: 998–1003.
Lie KI, Liem KL, Schuilenberg RM. Early identification of patients developing late in-hospital ventricular fibrillation after discharge from the coronary care unit: a 5.5 year retrospective study of 1897 patients. Am J Cardiol 1978; 41: 674–677.
Behar S, Goldbourt U, Reicher-Reiss H, Kaplinsky E, and the Principal Investigators of the SPRINT Study. Prognosis of acute myocardial infarction complicated by primary ventricular fibrillation. Am J Cardiol 1990; 66: 1208–1211.
Volpi A, Cavali A, Franzosi MG, et al. One year prognosis of primary ventricular fibrillation complicating acute myocardial infarction. Am J Cardiol 1989; 63: 1174–1178.
Lie KI, Wellens HJ, van Capelle FJ, Durrer D. Lidocaine in the prevention of primary ventricular fibrillation. N Engl J Med 1974; 291: 1324–1326.
DeSilva RA, Lown B, Hennekens CH, Casscells W. Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials. Lancet 1981; 2: 855–858.
MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized controlled trials. JAMA 1988; 260: 1910–1916.
Hine LK, Laird N, Hewitt P, Chalmers TC. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Int Med 1989; 149: 2694–2698.
Sadowski ZP, Alexander JH, Skrabucha B, et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am Heart J 1999; 137: 792–798.
Alexander JH, Granger CB, Sadowski Z, et al. Prophylactic lidocaine in use in acute myocardial infarction: incidence and outcomes from two international trials. Am Heart J 1999; 137: 799–805.
Koster RW, Dunning AJ. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospital phase of acute myocardial infarction. N Engl J Med 1985; 313: 1105–1110.
Velentine PA, Frew JL, Mashford ML, Sloman JG. Lidocaine in the prevention of sudden death in the pre-hospital phase of acute myocardial infarction: a double-blind study. N Engl J Med 1974; 291: 1327–1331.
Bernsten RF, Rasmussen K. Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. Am Heart J 1992; 124: 1478–1483.
Dunn HM, McComb JM, Kinney CD, et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. Am Heart J 1985; 110: 353–362.
Lie KI, Liem KL, Louridtz WJ, Janse MJ, Willebrands AF, Durrer D. Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. Am J Cardiol 1978; 42: 486–488.
Lie KI, Wellens HJJ, Downar E, Durrer D. Observations on patients with primary ventricular fibrillation complicating acute myocardial infarction. Circulation 1975; 52: 755–759.
El-Sharif N, Myerburg RJ, Scherlag BJ, et al. Electrocardiographic antecedents of primary ventricular fibrillation: value of the R-on-T phenomenon in myocardial infarction. Br Heart J 1976; 38: 415–422.
Ayanian JZ, Hauptman PJ, Guadagnoli E, et al. Knowledge and practice of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 1994;331:1136– 1142.
Elizari MV, Martinez JM, Belziti, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. Eur Heart J 2000; 21: 198–205.
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–371.
Norris RM, Brown MA, Clark ED, Barnaby PF, Geary GG, Logan RL. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranalol. Lancet 1984; 2: 883–886.
Ryde´n L, Ariniego R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction: effects on ventricular tachyarrhythmias. N Engl J Med 1983; 308: 614–618.
Yusuf S, Sleight P, Rossi P, et al. Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation 1983;67(Suppl I): I-32–I-41.
ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 2: 57–66.
Rapaport E. Should ß-blockers be given immediately and concomitantly with thrombolytic therapy in acute myocardial infarction? Circulation 1991; 83: 695–697.
Kennedy HL, Rosenson RS. Physician use of beta-adrenergic blocking therapy: a changing perspective. J Am Coll Cardiol 1995; 26: 547–552.
ISIS-4 Collaborative Group. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–685.
Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90: 2103–2114.
Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred (3-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B Study. Circulation 1991; 83: 422–437.
Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocker or a specific bradycardic agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 22: 407–416.
Pfisterer ME, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I Experience. J Am Coll Cardiol 1998; 32: 634–640.
Becker RC. Beta-adrenergic blockade following thrombolytic therapy: is it harmful or helpful? Clin Cardiol 1994; 17: 171–174.
Kafka H, Langeuin L, Armstrong PW. Serum magnesium and potassium in acute myocardial infarction: influence on ventricular arrhythmias. Arch Intern Med 1987; 147: 465–469.
Nordrehaug JE, von der Lippe G. Hypokalemia and ventricular fibrillation in acute myocardial infarction. Br Heart J 1983; 50: 525–529.
Nordrehaug JE, Johannessen K-A, von der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction. Circulation 1985; 71: 645–649.
Higham PD. Serum magnesium and ventricular fibrillation after myocardial infarction. Cardiovasc Res Rev 1994;11: 15–16, 18–19.
Horner SM. Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias
and morbidity: meta-analysis of magnesium in acute myocardial infarction. Circulation 1992;86:774– 779.
Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553–1558.
Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343: 816–819.
Antman EM. Randomized trials of magnesium in acute myocardial infarction: big numbers do not tell the whole story. Am J Cardiol 1995; 75: 391–393.
Shechter M, Hod H, Kaplinsky E, Chouraqui P, Rabinowitz B. Magnesium as alternate therapy in patients with acute myocardial infarction who are not candidates for thrombolytic therapy. Am J Cardiol 1995; 75: 321–323.
Pfeffer MA, Braunwald E, Moye LA, et al. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–677.
Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598–604.
Sogaard P, Gotzsche C-O, Ravkilde J, Norgaard A, Thygesen K. Ventricular arrhythmias in the acute and chronic phases after acute myocardial infarction: effect of intervention with captopril. Circulation 1994; 90: 101–107.
Kloner RA. Does reperfusion injury exist in humans? J Amer Coll Cardiol 1993; 21: 537–545.
GISSI Investigators. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–402.
ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 249–360.
Solomon SD, Ridker PM, Antman EM. Ventricular arrhythmias in trials of thrombolytic therapy for acute myocardial infarction: a meta-analysis. Circulation 1993; 88: 2575–2581.
Boissel J-P, Castaigne A, Mercier C, et al. Ventricular fibrillation following administration of thrombolytic treatment: The EMIP experience. Eur Heart J 1996; 17: 213–221.
Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673–679.
Singh BN. Routine prophylactic lidocaine administration in acute myocardial infarction: an idea whose time has come and gone? Circulation 1992; 86: 1033–1035.
Hargarten KM, Stueven HA, Waite EM, et al. Prehospital experience with defibrillation of coarse ventricular fibrillation: a ten-year review. Ann Emery Med 1990; 19: 157–162.
Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiac care. Circulation 2000; 102(Suppl I): I1–I384.
Haynes RE, Chinn TL, Copass MK, Cobb LA. Comparison of bretylium tosylate and lidocaine in management of out of hospital ventricular fibrillation: a randomized clinical trial. Am J Cardiol 1981; 48: 353–356.
Olson DW, Thompson BM, Darin JC, Milbrath MH. A randomised comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system. Ann Emerg Med 1984; 13: 807–810.
Feely J, Wilkinson GR, McAllister CB, Wood AJJ. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Int Med 1982; 96: 592–594.
Branch RA, Shand DG, Wilkinson GR, Nies AS. The reduction of lidocaine clearance by DLpropranolol: an example of haemodynamic drug interaction. J Pharmacol Exp Ther 1973; 184: 515–519.
Bacaner MB. Treatment of ventricular fibrillation and other acute arrhythmias with bretylium tosylate. Am J Cardiol 1968; 21: 530–543.
Heissenbuttel RH, Bigger TJ. Bretylium tosylate: a newly available antiarrhythmic drug for ventricular arrhythmias. Ann Int Med 1979; 91: 229–238.
Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997; 127: 294–303.
Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999; 341: 871–878.
Anastasiou-Nana MI, Nanas JN, Nanas SN, et al. Effects of amiodarone on refractory ventricular fibrillation in myocardial infarction: experimental study. J Am Coll Cardiol 1994; 23: 253–258.
Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991; 84: 1543–1551.
Eldar M, Sievner Z, Goldbourt U, et al. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. Ann Int Med 1992; 117: 31–36.
Mont L, Cinca J, Blanch P, et al. Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction. J Am Coll Cardiol 1996; 28: 1670–1676.
de Soyza N, Meacham D, Murphy ML, Kane JJ, Doherty JE, Bissett. Evaluation of warning arrhythmias before paroxysmal ventricular tachycardia during acute myocardial infarction in man. Circulation 1979; 60: 814–818.
de Soyza N, Bissett JK, Kane JJ, Murphy ML, Doherty JE. Association of accelerated idioventricular rhythm and paroxysmal ventricular tachycardia in acute myocardial infarction. Am J Cardiol 1974; 34: 667–670.
Cheema AN, Shehu K, Parker M, Kadish AH, Goldberger JL. Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics and their prognostic significance. Circulation 1998; 98: 2030–2036.
Josephson ME. Clin Cardiac Electrophysiol. Lea & Febiger, Philadelphia, PA 1993, 622–623.
Bhaskaran A, Seth A, Kumar A, et al. Coronary angioplasty for the control of intractable ventricular arrhythmia. Clin Cardiol 1995; 18: 480–483.
The ISAM Study Group. A prospective trial of Intravenous Streptokinase in Acute Myocardial infarction (ISAM): Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986;314:1465– 1471.
Wilcox RG, Eastgate J, Harrison E, Skene AM. Ventricular arrhythmia during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction. Br Heart J 1991; 65: 4–8.
Solomon SD, Antman EM. Prehospital thrombolytic therapy in patients with suspected myocardial infarction (letter). N Engl J Med 1994; 330: 291.
Krumholz HM, Goldberger AL. Reperfusion arrhythmias after thrombolysis: electrophysiologic tempest, or much ado about nothing. Chest 1991; 99(Suppl): 135S–140S.
Gorgels APM, Vos MA, Letsch IS, et al. Usefulness of the accelerated idioventricular rhythm as a marker for myocardial necrosis and reperfusion during thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1988; 61: 231–235.
Califf RM, O’Neill W, Stack RS, et al. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Int Med 1988; 108: 658–662.
DeSanctis RW, Block P, Hunter AM. Tachyarrhythmias in myocardial infarction. Circulation 1972; 45: 681–702.
Crimm A, Severance HW, Coffey K, McKinnis R, Wagner GS, Califf RM. Prognostic significance of isolated sinus tachycardia during the first three days of acute myocardial infarction. Am J Med 1984; 76: 983–988.
Behar S, Zahavi Z, Goldbourt U, Reicher-Reiss H, and the SPRINT Study Group. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. Eur Heart J 1992; 13: 45–50.
Goldberg RJ, Seeley D, Becker RC, et al. Impact of atrial fibrillation on the in-hospital and longterm survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1990; 119: 996–1001.
Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation 2000; 101: 969–974.
Serrano CV, Ramires JAF, Mansur AP, Pileggi F. Importance of the time of onset of supraventricular tachyarrhythmias on prognosis of patients with acute myocardial infarction. Clin Cardiol 1995; 18: 84–90.
Sugiura T, Takahashi N, Nakamura S, et al. Atrial fibrillation in inferior Q-wave acute myocardial infarction. Am J Cardiol 1991; 67: 1135–1136.
Nielsen FE, Andersen HH, Gram-Hansen P, Sørensen HT, Klausen IC. The relationships between ECG signs of atrial infarction and the development of supraventricular arrhythmias in patients with acute myocardial infarction. Am Heart J 1992; 123: 69–72.
Hod H, Lew AS, Keltai M, et al. Early atrial fibrillation during evolving myocardial infarction: a consequence of impaired left atrial perfusion. Circulation 1987; 75: 146–150.
Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1997; 30: 406–413.
Cowan JC, Gardiner P, Reid DS, Newell DJ, Campbell RWF. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating acute myocardiovasc infarction. J Cardiac Pharmacol 1986; 8: 252–256.
Kober L, the Diamond Study Group. A clinical trial of dofetilide in patients with acute myocardial infarction and left ventricular dysfunction. The Diamond MI study. Circulation 1998; 98: 1–93.
Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995; 332: 162–173.
Mehta D, Ward DE, Wafa S, Camm AJ. Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. Lancet 1988; 1: 1181–1185.
Moller B, Ringqvist C. Metoprolol in the treatment of supraventricular tachyarrhythmias. Ann Clin Res 1979; 11: 34–41.
Konecke LL, Knoebel SB. Nonparoxysmal junctional tachycardia complicating acute myocardial infarction. Circulation 1972; 45: 367–374.
Fishenfeld J, Desser KB, Benchimol A. Non-paroxysmal A-V junctional tachycardia associated with acute myocardial infarction. Am Heart J 1973; 86: 754–758.
Mangrum JM, DiMarco JP. The evaluation and management of bradycardia. N Engl J Med 2000; 342: 703–709.
Scheinman MM, Gonzalez RP. Fascicular block in acute myocardial infarction. JAMA 1980; 244: 2646–2649.
Lown B, Klein MD, Hershberg PI. Coronary and precoronary care. Am J Med 1969; 46: 705–724.
Adgey AAJ, Mulholland HC, Geddes JS, Keegan DAJ, Pantridge JF. Incidence, significance, and management of early bradyarrhythmia complicating acute myocardial infarction. Lancet 1968;2:1097– 1101.
Rotman M, Wagner GS, Wallace AG. Bradyarrhythmias in acute myocardial infarction. Circulation 1972; 45: 703–722.
Webb S, Adgey AAJ, Pantridge JF. Autonomic dysfunction at onset of acute myocardial infarction. Br Med J 1972; 3: 89–92.
Koren G, Weiss AT, Ben-David J, Hasin Y, Luria MH, Gotsman MS. Bradycardia and hypotension following reperfusion with streptokinase (Bezold-Jarisch reflex): a sign of coronary thrombolysis and myocardial salvage. Am Heart J 1986; 112: 468–471.
Thames MD, Klopfenstein HS, Abboud FM, Allyn ML, Walker JL. Preferential distribution of inhibitory cardiac receptors with vagal afferents to the inferoposterior wall of the left ventricle during coronary occlusion in the dog. Circ Res 1978; 43: 512–519.
Norris RM, Mercer CJ, Yeater SE. Sinus rate in acute myocardial infarction. Br Heart J 1972;34:901– 904.
Come PC, Pitt B. Nitroglycerin-induced severe hypotension and bradycardia in patients with acute myocardial infarction. Circulation 1976; 54: 624–628.
Kottmeier CA, Gravenstein JS. The parasympathomimetic activity of atropine and atropine methylbromide. Anesthesiology 1968; 29: 1125–1133.
Massimi RA, Mason DT, Amsterdam EA, et al. Ventricular fibrillation after intravenous atropine for treatment of bradycardias. N Engl J Med 1972; 287: 336–338.
Cooper MJ, Abinader EG. Atropine-induced ventricular fibrillation: case report and review of the literature. Am Heart J 1979; 97: 225–228.
Johansson BW. Atrioventricular and bundle branch block in acute myocardial infarction: natural history and prognosis. In: Meltzer LE, Dunning AJ, eds. Textbook of Coronary Care. The Charles Press Publishers, Inc., MD, 1972, pp. 328–340.
Bhandari AK, Sager PT. Management of peri-infarctional ventricular arrhythmias and conduction disturbances. In: Naccarelli GV, ed. Cardiac Arrhythmias: A Practical Approach. Futura Publishing Company, Inc., Mount Kisco, N.Y., 1991, pp. 283–324.
Behar S, Zissman E, Zion M, et al. Complete atrioventricular block complicating inferior wall myocardial infarction: short and long-term prognosis. Am Heart J 1993; 125: 1622–1627.
Clemmensen P, Bates ER, Califf RM, et al. Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. Am J Cardiol 1991; 67: 225–230.
Braat SH, de Zwaan C, Brugada P, Loenegracht JM, Wellens HJJ. Right ventricular involvement with acute inferior myocardial infarction identifies high risk of developing atrioventricular nodal conduction disturbances. Am Heart J 1984; 107: 1183–1187.
Zehender M, Kasper W, Kauder E, et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 1993; 328: 981–988.
Berger PB, Ruoccona NA, Ryan TJ, et al. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. J Am Coll Cardiol 1992; 20: 533–540.
Goldberg RJ, Zevallos JC, Yarzebski, et al. Prognosis of acute myocardial infarction complicated by complete heart block (the Worcester Heart Attack Study). Am J Cardiol 1992; 69: 1135–1141.
Mavric Z, Zaputovic L, Matana A, et al. Prognostic significance of complete atrioventricular block in patients with acute inferior myocardial infarction with and without right ventricular involvement. Am Heart J 1990; 119: 823–828.
Simons GR, Sgarbossa E, Wagner G, et al. Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. PACE 1998; 2651–2663.
Shah PK, Peter T. Atropine resistant post infarction complete AV block: Possible role of adenosine and improvement with aminophylline. Am Heart J 1987; 113: 194–195.
Strasgerg B, Bassevich R, Mager A, Kusniec J, Sagie A, Sclarovsky S. Effects of aminophylline on atrioventricular conduction in patients with late atrioventricular block during inferior wall acute myocardial infarction. Am J Cardiol 1991; 67: 527–528.
Ip JH. Intraventricular conduction disturbances in patients with acute myocardial infarction: indications for a temporary pacemaker. Cardiovasc Res Rev 1990; 46–48.
Klein RC, Vera Z, Mason DT. Intraventricular conduction defects in acute myocardial infarction: incidence, prognosis, and therapy. Am Heart J 1984; 108: 1007–1013.
Hollander G, Nadiminti V, Lichstein E, Greengart A, Sanders M. Bundle branch block in acute myocardial infarction. Am Heart J 1983; 105: 738–743.
Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction: 1. Clinical characteristics, hospital mortality, and one-year follow-up. Circulation 1978; 58: 679–688.
Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, Zipes DP, Libby P. eds. Heart Disease 6th ed. Philadelphia: W.B. Saunders, 2001, pp. 114–1231.
Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction: 2. Indications for temporary and permanent pacemaker insertion. Circulation 1978; 58: 689–699.
Ricou F, Nicod P, Gilpin E, Henning H, Ross J. Influence of right bundle branch block on short-and long-term survival after acute anterior myocardial infarction. J Am Coll Cardiol 1991; 17: 858–863.
Ricou F, Nicod P, Gilpin E, Henning H, Ross J. Influence of right bundle branch block on short-and long-term survival after inferior Q-wave myocardial infarction. Am J Cardiol 1991; 67: 1143–1146.
Go AS, Barron HV, Rundle AC, et al. Bundle-branch block and in-hospital mortality in acute myocardial infarction. Ann Intern Med 1998; 129: 690–697.
Sgarbossa EB, Pinski SL, Topol EJ, et al. Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. J Am Coll Cardiol 1998; 31: 105–110.
Lieberman EH, Aude YW. Permanent cardiac pacing after acute myocardial infarction. Cardiovasc Electrophysiol Rev 1999; 2: 377–380.
Willems AR, Tijssen JG, van Capelle FJL, et al. Determinants of prognosis in symptomatic ventricular tachycardia or ventricular fibrillation late after myocardial infarction. J Am Coll Cardiol 1990;16:521– 530.
The AVID Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1998; 337: 1576–1583.
Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297– 1302.
Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748–754.
Moss AJ, Hall WJ, Cannom D, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med 1996; 335: 1933–1940.
Buxton AE, Fisher JD, Lee KL, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882–1890.
Bigger JT. Prophylactic use of implanted cardiac defibrillators at high risk for ventricular arrhythmias after coronary-bypass graft surgery. N Engl J Med 1997; 337: 1569–1575.
Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM, and the Multicenter Post-Infarction Research Group. The relationships between ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69: 250–258.
Hallstrom AP, Bigger JT Jr, Roden D, et al. Prognostic significance of ventricular premature depolarizations measured one year after myocardial infarction in patients with early postinfarction ventricular arrhythmia. J Am Coll Cardiol 1992; 20: 259–264.
Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 782–788.
The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227–233.
Hine LK, Laird NM, Hewitt P, Chalmers TC. Meta-analysis of empirical long-term antiarrhythmic therapy after acute myocardial infarction. JAMA 1989; 262: 3037–3040.
Teo KT, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993; 270: 1589–1595.
Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675–682.
Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction. EMIAT. Lancet 1997; 349: 667–674.
Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 1417–1424.
Julian DG, Jackson FS, Prescott RJ, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1142–1147.
Waldo AL, Camm AJ, de Ruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7–12.
Camm AJ, Karam R, Pratt CM. The azimilide post-infarct survival trial evaluation (ALIVE). Am J Cardiol 1998; 81: 35D–39D.
Avanzini F, Latini R, Maggioni A, et al. Antiarrhythmic drug prescription in patients after myocardial infarction in the last decade: experience of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarcto miocardio (GISSI). Arch Intern Med 1995; 155: 1041–1045.
Maggiona AP, Zuanetta G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the thrombolytic era. Circulation 1993; 87: 312–322.
Mukharji J, Rude RE, Poole K, et al. Risk factors for sudden death after acute myocardial infarction: two year follow-up. Am J Cardiol 1984; 54: 31–36.
Bourke JP, Richards DAB, Ross DL, Wallace EM, McGuire MA, Other JB. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol, and cost-effective screening. J Am Coll Cardiol 1991; 18: 780–788.
Gang ES, Lew AS, Hong M, Wang F, Siebert CA, Peter T. Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med 1989; 321: 712–716.
Pedretti R, Laporta A, Etro MD, et al. Influence of thrombolysis on signal-averaged electrocardiogram and late arrhythmic events after acute myocardial infarction. Am J Cardiol 1992; 69: 866–872.
McClements BM, Adgey AAJ. Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era. J Am Coll Cardiol 1993; 21: 1419–1427.
Hayano J, Sakakibara Y, Yamada M, et al. Accuracy of assessment of cardiac vagal tone by heart rate variability. Am J Cardiol 1991; 67: 199–204.
Kjellgren O, Gomes JA. Heart rate variability and baroreflex sensitivity in myocardial infarction. Am Heart J 1993; 125: 204–215.
Kleiger RE, Miller JP, Bigger JT, Moss AJ, and the Multicenter Post-Infarction Research Group.Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256–262.
Pedretti RF, Colombo E, Braga SS, Caru B. Effect of thrombolysis on heart rate variability and life-threatening ventricular arrhythmias in survivors of acute myocardial infarction. J Am Coll Cardiol 1994; 23: 19–26.
Perkiomaki JS, Koistinen MJ, Yli-Mayry S, Huikuri HV. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmia after previous myocardial infarction. J Am Coll Cardiol 1995; 26: 174–179.
Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 1994; 330: 235–241.
Hohnloser SH, Franck P, Klingenheber T, Zabel M, Just H. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era—A prospective trial. Circulation 1994; 90: 1747–1756.
Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991; 18: 687–697.
La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction: ATRAMI. Lancet 1998; 351: 478–484.
Moss AJ, Cannom DS, Daubert JP, et al. Multicenter automatic defibrillator implantation trial II (MADIT II): Design and clinical protocol. Ann Noninvasiv Electrocardiol 1999; 4: 83–91.
The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–807.
ß-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results. JAMA 1982; 247: 1707–1714.
Kendall MJ, Lynch HP, Hjalmarson A, Kjekshus J. B-blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358–367.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ganz, L.I., Antman, E.M. (2002). Cardiac Arrhythmias During Acute Myocardial Infarction. In: Ganz, L.I. (eds) Management of Cardiac Arrhythmias. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-090-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-59259-090-2_19
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-218-6
Online ISBN: 978-1-59259-090-2
eBook Packages: Springer Book Archive